Disclosure Of First-Time Adoption [Text Block]

OSE Immunotherapeutics - Filing #2813125

Concept	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31
Disclosure of first-time adoption [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of comparative information prepared under previous GAAP [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of comparative information prepared under previous GAAP [abstract]
Disclosure of comparative information prepared under previous GAAP [line items]
Equity	32 658 EUR	—	—	—	35 890 EUR	65 611 EUR	549,000 EUR	3 705 EUR	220,000 EUR	—	—	—	160,000 EUR	—	47 890 EUR	—	—	—	21 111 EUR	65 605 EUR	150,000 EUR	3 705 EUR	—	—	3 597 EUR	7 485 EUR	93,000 EUR	104,000 EUR	65 449 EUR	61 364 EUR
Comprehensive income	—	0 EUR	0 EUR	17 699 EUR	—	—	—	—	—	17 638 EUR	0 EUR	61,000 EUR	—	0 EUR	—	16 825 EUR	0 EUR	55,000 EUR	—	—	—	—	0 EUR	16 879 EUR	—	—	—	—	—	—
Profit (loss)	—	—	—	17 760 EUR	—	—	—	—	—	17 760 EUR	—	—	—	—	—	16 850 EUR	—	—	—	—	—	—	—	16 850 EUR	—	—	—	—	—	—